Answers are grounded in this paper and cite their sources.
Review highlights AI's role in enhancing diagnosis and therapeutic decision-making in valvular heart disease.
Valvular heart disease (VHD) is emerging as the next major epidemic in cardiovascular care, driven by the aging population. The advent of less invasive alternatives to surgery—namely, transcatheter therapies—has revolutionized patient management, while simultaneously introducing new layers of complexity. Artificial intelligence (AI) holds significant promise to transform the care of patients with VHD across all dimensions, including diagnosis, prognostication, disease progression, and therapeutic decision-making. In this review, we provide a comprehensive overview of the current evidence, and discuss the challenges, risks, and future directions associated with the integration of AI in the management of VHD.
No takes yet. Share an insight, caveat, or question.
Thériault-Lauzier et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: